GlassScriptPhysician profile
Thanh T Le
NPI 1134165350
$13,716.69
in general payments reported to CMS, 2019-2025
52 companies · $2,532 in 2025
The $2,532 reported for 2025 was more than what 76% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $904 · 2020: $1,525 · 2021: $2,057 · 2022: $1,812 · 2023: $2,339 · 2024: $2,547 · 2025: $2,532.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,374 · Education: $43.82.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,374.12 |
| Education | $43.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $2,643.61 | 2019-2025 | Briviact, Fintepla, Nayzilam |
| Abbvie INC. | $2,342.30 | 2021-2025 | |
| Supernus Pharmaceuticals, INC. | $975.45 | 2019-2025 | Qelbree, Qelbree |
| Sk Life Science, INC. | $701.11 | 2020-2025 | Xcopri |
| Tris Pharma INC | $676.44 | 2019-2025 | Dyanavel Xr, Onyda Xr |
| Neurelis, INC. | $528.01 | 2020-2025 | Valtoco |
| Corium, LLC | $513.28 | 2022-2025 | Azstarys |
| Takeda Pharmaceuticals U.S.A., INC. | $451.35 | 2020-2022 | |
| Csl Behring | $339.75 | 2022-2025 | Hizentra |
| Eisai INC. | $336.83 | 2020-2022 | |
| Pfizer INC. | $277.11 | 2023-2025 | |
| Biogen, INC. | $273.95 | 2020-2025 | Vumerity, Tysabri |
| Aquestive Therapeutics, INC. | $239.46 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $228.51 | 2019-2023 | Austedo Xr |
| Neurocrine Biosciences, INC. | $218.61 | 2023-2025 | Ingrezza |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thanh Le listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.